LUND, Sweden, April 12, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that Oncurious NV has presented data from a phase I dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB) at the...